Stockscreener 앱 받기
10.20
0.99%
0.10
시간 외 거래:
10.06
-0.14
-1.37%
전일 마감가:
$10.10
열려 있는:
$10.325
하루 거래량:
2.31M
Relative Volume:
0.54
시가총액:
$647.71M
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-4.4348
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
+1.29%
1개월 성능:
+21.00%
6개월 성능:
-75.90%
1년 성능:
-78.19%
1일 변동 폭
$10.06
$10.55
1주일 범위
$9.37
$10.55
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
MLTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
10.20 | 641.36M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
Deadline Alert: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
MLTX Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MLTX To Contact Him Directly To Discuss Their Options - MarketScreener
MLTX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MLTX To Contact Him Directly To Discuss Their Options - PR Newswire
Securities Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (MLTX)Levi & Korsinsky Represents Shareholders - The Globe and Mail
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Acti - GuruFocus
MLTX CLASS ACTION NOTICE: Berger Montague Encourages MoonLake Immunotherapeutics (NASDAQ - MarketScreener
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener
MLTX INVESTOR CLASS ACTION: MoonLake Immunotherapeutics has - GlobeNewswire
H.C. Wainwright upgrades Moonlake stock rating to Buy with $30 price target - Investing.com
HC Wainwright & Co. Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
2025-11-02 | Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX)Contact Levi & Korsinsky Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
2025-11-02 | MLTX ALERT: Securities Fraud Class Action Launched Against MoonLake ImmunotherapeuticsDecember 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to ... - Bluefield Daily Telegraph
Quantitative breakdown of MoonLake Immunotherapeutics recent moveTrade Analysis Summary & Verified Entry Point Detection - newser.com
Can MoonLake Immunotherapeutics stock deliver sustainable ROEJuly 2025 Gainers & Verified Technical Signals - newser.com
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Shou - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 6.7% HigherShould You Buy? - MarketBeat
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against - PR Newswire
Levi & Korsinsky Notifies MoonLake Immunotherapeutics (MLTX) InvestorsLead Plaintiff Deadline on December 15, 2025 - Newsfile
MoonLake Immunotherapeutics Securities Fraud Class Action - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Faces Securities Class - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
Visualizing MoonLake Immunotherapeutics stock with heatmapsJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Can MoonLake Immunotherapeutics stock beat analyst upgradesJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
How MoonLake Immunotherapeutics stock trades during market volatilityQuarterly Trade Summary & Verified Entry Point Signals - newser.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming DeadlinesMLTX - FinancialContent
MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman - Morningstar
The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming DeadlineMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) - openPR.com
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - MarketScreener
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - Nasdaq
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi - TipRanks
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
MOONLAKE IMMUNOTHERAPEUTICS SECURITIES FRAUD NOTICE: Berger Montague Informs MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Securities Fraud Lawsuit - Your Wyoming Link
Is MoonLake Immunotherapeutics stock resilient to inflationWeekly Trading Summary & Reliable Breakout Stock Forecasts - Fundação Cultural do Pará
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - Morningstar
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):